nach oben

Erschienen in:

01.03.2009

Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity

verfasst von: Ayumi Yoshizaki, Kazuhiro Komura, Yohei Iwata, Fumihide Ogawa, Toshihide Hara, Eiji Muroi, Motoi Takenaka, Kazuhiro Shimizu, Minoru Hasegawa, Manabu Fujimoto, Shinichi Sato

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The high mobility group box 1 protein (HMGB-1)/advanced glycation end products (RAGE) system is recently shown to play an important part in immune/inflammatory disorders. However, the association of this system in systemic sclerosis (SSc) remains unknown.

Materials and Methods

To determine clinical association of serum levels of HMGB-1 and soluble RAGE (sRAGE) in patients with SSc, sera from 70 patients with SSc and 25 healthy controls were examined by enzyme-linked immunosorbent assay. Sera from tight-skin mice and bleomycin-induced scleroderma mice, animal models for SSc, were also examined. Skin HMGB-1 and RAGE expression was assessed by immunohistochemistry.

Results and Discussion

Serum HMGB-1 and sRAGE levels in SSc were higher than those in controls. Similarly, HMGB-1 and sRAGE levels in animal SSc models were higher than those in control mice. SSc patients with elevated HMGB-1 and sRAGE levels had more frequent involvement of several organs and immunological abnormalities compared to those with normal levels. Furthermore, HMGB-1 and sRAGE levels correlated positively with modified Rodnan total skin thickness score and negatively with pulmonary function test.

Conclusions

HMGB-1 and sRAGE expression in the sclerotic skin was more intense than normal skin. These results suggest that elevated serum HMGB-1 and sRAGE levels are associated with the disease severity and immunological abnormalities in SSc.

Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol. 2003;120:542–7. doi:10.1046/j.1523-1747.2003.12097.x.PubMedCrossRef

La Montagna G, D’Angelo S, Valentini G. Cross-sectional evaluation of ykl-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol. 2003;30:2147–51.PubMed

Szegedi A, Czirjak L, Unkeless JC, Boros P. Serum cytokine and anti-fc gamma r autoantibody measurements in patients with systemic sclerosis. Acta Derm Venereol. 1996;76:21–3.PubMed

Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol. 2006;18:579–81. doi:10.1097/01.bor.0000245726.33006.c3.PubMedCrossRef

Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006;291:C1318–25. doi:10.1152/ajpcell.00616.2005.PubMedCrossRef

Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5:825–30. doi:10.1038/sj.embor.7400205.PubMedCrossRef

Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26:381–7. doi:10.1016/j.it.2005.04.009.PubMedCrossRef

Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. Hmg-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51. doi:10.1126/science.285.5425.248.PubMedCrossRef

Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42. doi:10.1038/nri1594.PubMedCrossRef

10.

Bartling B, Fuchs C, Silber RE, Simm A. Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors. Int J Mol Med. 2007;20:217–24.PubMed

11.

Ren D, Sun R, Wang S. Role of inducible nitric oxide synthase expressed by alveolar macrophages in high mobility group box 1-induced acute lung injury. Inflamm Res. 2006;55:207–15. doi:10.1007/s00011-006-0072-2.PubMedCrossRef

12.

Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and rage. Nat Immunol. 2007;8:487–96. doi:10.1038/ni1457.PubMedCrossRef

13.

Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (rage) directly binds to ERK by a d-domain-like docking site. FEBS Lett. 2003;550:107–13. doi:10.1016/S0014-5793(03)00846-9.PubMedCrossRef

14.

Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res. 1999;71:159–70. doi:10.1016/S0169-328X(99)00174-6.PubMedCrossRef

15.

Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–109. doi:10.1042/BJ20021371.PubMedCrossRef

16.

Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (rage) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol. 2004;40:1203–11. doi:10.1016/j.molimm.2003.11.027.PubMedCrossRef

17.

Nawroth PP, Stern DM. Soluble forms of rage: an index of vascular stress? A commentary on “Soluble rage in type 2 diabetes: association with oxidative stress”. Free Radic Biol Med. 2007;43:506–10. doi:10.1016/j.freeradbiomed.2007.04.014.PubMedCrossRef

18.

Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170:1310–6. doi:10.1164/rccm.200402-188OC.PubMedCrossRef

19.

Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94:975–9.PubMed

20.

Kim JY, Park JS, Strassheim D, Douglas I, Diaz del Valle F, Asehnoune K, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005;288:L958–65. doi:10.1152/ajplung.00359.2004.PubMedCrossRef

21.

Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Synovial fluid expression of autoantibodies specific for rage relates to less erosive course of rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1367–71. doi:10.1093/rheumatology/kem141.CrossRef

22.

Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:R817–24. doi:10.1186/ar1749.PubMedCrossRef

23.

Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008;147:79–83.PubMedCrossRef

24.

Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999;112:456–62. doi:10.1046/j.1523-1747.1999.00528.x.PubMedCrossRef

25.

Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol. 1976;82:493–512.PubMed

26.

Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90. doi:10.1002/art.1780230510.CrossRef

27.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed

28.

Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobeservar variability in 3 independent studies. J Rheumatol. 1993;20:1892–6.PubMed

29.

Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum. 1994;37:391–4. doi:10.1002/art.1780370313.PubMedCrossRef

30.

Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K, et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology. 2001;40:406–109. doi:10.1093/rheumatology/40.4.406.CrossRef

31.

Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48:2052–8. doi:10.1002/art.11161.PubMedCrossRef

32.

Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003;10:445–8.PubMed

33.

Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006;73:158–65. doi:10.1016/j.diabres.2005.12.013.PubMedCrossRef

34.

Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med. 1998;36:251–9.PubMed

35.

Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res. 2006;297:333–44. doi:10.1007/s00403-005-0635-z.PubMedCrossRef

36.

Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. Rage mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell. 1999;97:889–901. doi:10.1016/S0092-8674(00)80801-6.PubMedCrossRef

37.

Li J, Schmidt AM. Characterization and functional analysis of the promoter of rage, the receptor for advanced glycation end products. J Biol Chem. 1997;272:16498–506. doi:10.1074/jbc.272.26.16498.PubMedCrossRef

38.

Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006;55:1227–31. doi:10.1016/j.metabol.2006.05.007.PubMedCrossRef

39.

Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2003;279:7370–7. doi:10.1074/jbc.M306793200.PubMedCrossRef

40.

Lin KI, Kao YY, Kuo HK, Yang WB, Chou A, Lin HH, et al. Reishi polysaccharides induce immunoglobulin production through the tlr4/tlr2-mediated induction of transcription factor blimp-1. J Biol Chem. 2006;281:24111–23. doi:10.1074/jbc.M601106200.PubMedCrossRef

41.

Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2006;54:2289–94. doi:10.1002/art.21969.PubMedCrossRef

42.

Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005;52:3639–45. doi:10.1002/art.21398.PubMedCrossRef

43.

Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, et al. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 2008;14:1–15. doi:10.2119/2007-00107.CrossRef

44.

van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products (rage) in HMGB1 induced inflammation in vivo. Shock. 2008. PMID: 18665043.

45.

Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005;33:564–73. doi:10.1097/01.CCM.0000155991.88802.4D.PubMedCrossRef

46.

Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S, Ulfgren AK, et al. Systemic tnf blockade does not modulate synovial expression of the pro-inflammatory mediator hmgb1 in rheumatoid arthritis patients—a prospective clinical study. Arthritis Res Ther. 2008;10:R33. doi:10.1186/ar2387.PubMedCrossRef

47.

Kielty CM, Raghunath M, Siracusa LD, Sherratt MJ, Peters R, Shuttleworth CA, et al. The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol. 1998;140:1159–66. doi:10.1083/jcb.140.5.1159.PubMedCrossRef

48.

Bona C, Rothfield N. Autoantibodies in scleroderma and tightskin mice. Curr Opin Immunol. 1994;6:931–7. doi:10.1016/0952-7915(94)90016-7.PubMedCrossRef

49.

Inghilleri S, Morbini P, Oggionni T, Barni S, Fenoglio C. In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochem Cell Biol. 2006;125:661–9. doi:10.1007/s00418-005-0116-7.PubMedCrossRef

50.

Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of rage-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354–60. doi:10.1038/35012626.PubMedCrossRef

51.

Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (rage) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507–15. doi:10.1084/jem.20030800.PubMedCrossRef

52.

Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Serum levels of srage, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med. 2007;13:1–9. doi:10.2119/2006-00090.CrossRef

53.

Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology. 2006;45:815–8. doi:10.1093/rheumatology/kel012.PubMedCrossRef

54.

Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2000;155:1–15. doi:10.1016/S0300-483X(00)00272-9.PubMedCrossRef

Titel: Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity
verfasst von: Ayumi Yoshizaki
Kazuhiro Komura
Yohei Iwata
Fumihide Ogawa
Toshihide Hara
Eiji Muroi
Motoi Takenaka
Kazuhiro Shimizu
Minoru Hasegawa
Manabu Fujimoto
Shinichi Sato
Publikationsdatum: 01.03.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 2/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9252-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity

Abstract

Introduction

Materials and Methods

Results and Discussion

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Materials and Methods

Results and Discussion

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Human Immune Memory to Yellow Fever and Smallpox Vaccination

HLA Class II (DRB, DQA1 and DQB1) Allele and Haplotype Frequencies in the Patients with Pemphigus Vulgaris

5′ Regulatory and 3′ Untranslated Region Polymorphisms of Vitamin D Receptor Gene in South Indian HIV and HIV–TB Patients

Chinese Patients with Defective IL-12/23-Interferon-γ Circuit in Taiwan: Partial Dominant Interferon-γ Receptor 1 Mutation Presenting as Cutaneous Granuloma and IL-12 Receptor β1 Mutation as Pneumatocele

Serological Responses to Microbial Antigens in Celiac Disease Patients During a Gluten-Free Diet

Long-Term Neurocognitive Function of Pediatric Patients with Severe Combined Immune Deficiency (SCID): Pre- and Post-Hematopoietic Stem Cell Transplant (HSCT)

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin